Research ArticleResearchMedication SafetyPatient Education

Liver resection prolonged treatment control after atezolizumab-bevacizumab response in selected HCC

Lancet (PubMed)Aug 22, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

In the TALENTOP phase 3 trial, liver resection after response or stable disease on atezolizumab plus bevacizumab prolonged time to treatment failure versus maintenance therapy in a selected locally advanced HCC population, with more serious treatment-related adverse events.

What NurseJet pulled from the source

After induction therapy, 201 of 489 enrolled patients with macrovascular invasion, no extrahepatic metastasis, and resectable response or stable disease were randomized. Median time to treatment failure was 20.4 months with resection plus postoperative therapy versus 11.8 months with maintenance therapy. Grade 3-4 treatment-related adverse events occurred in 39% versus 21%, and two treatment-related deaths occurred in the surgery group.

Why this matters for nurses

Oncology and perioperative nurses may encounter carefully selected patients moving from systemic therapy to liver surgery and back to postoperative therapy. The benefit-risk conversation must include both longer treatment control and the higher treatment-related toxicity observed in the surgical strategy.

Bedside takeaway

Selected HCC responders had longer treatment control with resection, but serious toxicity was more frequent and selection was narrow.

How This Applies in Practice

Use this when: Caring for a patient with locally advanced HCC transitioning between atezolizumab-bevacizumab therapy and planned liver resection.

On your shift

Confirm the current treatment phase, last systemic-therapy dose, operative plan, and authorized monitoring schedule.
Trend ordered liver tests, platelet counts, urine protein, and postoperative findings using the approved oncology-surgical workflow.
Escalate hepatic dysfunction, thrombocytopenia, proteinuria, or other severe symptoms through the oncology-surgical pathway.

Keep in mind: The trial does not support surgery for every patient with advanced HCC. Follow the multidisciplinary treatment plan, facility policy, and provider orders.

Key takeaways

Only 201 of 489 induction-phase participants met response, disease-distribution, and resectability criteria and were randomized.
Median time to treatment failure was 20.4 months with resection versus 11.8 months with maintenance therapy.
Grade 3-4 treatment-related adverse events occurred in 39% of assessed surgery-group patients and 21% of maintenance-group patients.
Two treatment-related deaths occurred in the surgery group; the trial remains ongoing and overall survival was not the reported primary endpoint.

Practice implications

Verify the treatment phase and planned timing of therapy around surgery, monitor ordered liver-function, platelet, and urine-protein measures plus the postoperative assessment, and escalate abnormalities through the oncology-surgical pathway. Do not generalize this strategy to patients who did not meet the trial's selection criteria.

Limitations & cautions

The open-label trial enrolled patients at 24 hospitals in China and randomized only selected responders without extrahepatic metastasis who were considered resectable. Follow-up was 18.4 months, the primary endpoint was time to treatment failure rather than overall survival, and the study was funded in part by the drug manufacturer.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Lancet (PubMed)

Lancet (PubMed). Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42624156/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Supportive care in cancer (PubMed)Sep 5, 2026Research Article

A small randomized trial found larger one-month reductions in reported supportive-care needs among colorectal cancer caregivers who received smartphone-based education than with routine care.

OncologyAI summaryReview source

Research ArticleResearchPatient EducationAI summary · original source linked below

Eighty family caregivers at two teaching hospitals in Tehran were randomized. Compared with routine care, the intervention group reported larger reductions in total needs and in health-service, psychological-emotional, work-social, and information domains after four weeks.

Key takeaways

The intervention was designed around family caregivers' supportive-care needs.
All four measured need domains favored the smartphone-education group at four weeks.
The abstract reports statistical significance but does not provide effect sizes or describe the educational content in detail.

Why this matters on shift

Caregiver education is part of oncology care, and mobile delivery may extend structured support beyond brief in-person teaching encounters.

Bedside takeaway

Ask caregivers about unmet information and support needs, then reinforce teaching with approved digital resources.

Nursing implications

Assess what caregivers still need to know and use approved digital education as a supplement to individualized teaching and follow-up.

Limitations & cautions

Abstract-only summary. The trial included 80 caregivers at two hospitals, assessed self-reported needs after only four weeks, and did not report patient outcomes or effect sizes in the abstract.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Supportive care in cancer (PubMed). The effect of a smartphone-based educational intervention on the supportive care needs of family caregivers of patients with colorectal cancer: a randomized controlled trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

The New England journal of medicine (PubMed)Sep 3, 2026Research ArticlePractice applicable

A phase 2 randomized trial favored azacitidine-venetoclax over induction chemotherapy for event-free survival in selected adults with untreated AML.

Oncology Med-SurgAI summaryReview source

Research ArticleResearchMedication SafetyPractice applicableAI summary · original source linked below

Among 172 participants, median event-free survival was 14.5 versus 6.2 months (hazard ratio for event or death 0.57; 95% CI 0.39-0.84). Median follow-up was 21.9 months.

Key takeaways

Grade 3 or higher infection occurred in 28% versus 41%, respectively.
Grade 3 or higher hemorrhage occurred in 2% versus 12%, respectively.

Why this matters on shift

The result informs treatment discussions, while serious infection and bleeding remain relevant nursing concerns.

Bedside takeaway

Avoid generalizing this phase 2 result to every patient with AML.

Nursing implications

Reinforce the individualized oncology plan and communicate infection or bleeding concerns promptly.

Limitations & cautions

Abstract-only summary of an industry-funded phase 2 trial. Core-binding-factor fusions, FLT3 mutations, and NPM1 mutations in patients under 60 were excluded. Event-free survival is not overall survival.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

The New England journal of medicine (PubMed). Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

The American journal of managed care (PubMed)Aug 1, 2026Research ArticlePractice applicable

A post hoc randomized-trial analysis found lower symptom-management self-efficacy identified breast cancer survivors with poorer outcomes who appeared to benefit most from remote monitoring plus tailored messages.

Oncology Med-SurgAI summaryReview source

Research ArticleResearchPatient EducationWorkflowPractice applicableAI summary · original source linked below

The analysis included 264 women prescribed adjuvant endocrine therapy and compared enhanced usual care, weekly app monitoring, and app monitoring plus tailored supportive texts. Higher baseline self-efficacy was associated with lower symptom burden and greater adherence. At a low self-efficacy score of 30, estimated adherence was 52.7% with app plus feedback versus 17.8% with usual care, but the confidence interval was wide and the subgroup analysis was post hoc.

Key takeaways

The post hoc analysis included 264 women from a randomized trial of app-based symptom and adherence monitoring.
Higher baseline symptom-management self-efficacy was associated with lower symptom burden and greater odds of endocrine-therapy adherence.
The tailored-feedback intervention showed its largest estimated adherence benefit at lower self-efficacy levels.
The low-self-efficacy estimate had a wide confidence interval, and effects diminished and became nonsignificant at higher self-efficacy levels.

Why this matters on shift

Endocrine-therapy symptoms and low confidence managing them can undermine long-term treatment. Oncology nurses can identify support needs, normalize symptom reporting, and close the loop with the oncology team while recognizing that an app is an adjunct rather than a replacement for care.

Bedside takeaway

Low confidence managing endocrine-therapy symptoms can be a cue for more tailored follow-up and adherence support.

Nursing implications

Ask how confident the patient feels managing symptoms and the daily regimen, then assess barriers, symptom burden, missed doses, and support preferences. Route concerns through the survivorship or oncology pathway and use remote monitoring only within the approved program.

Limitations & cautions

This was a post hoc effect-modification analysis rather than a prespecified primary comparison. Adherence was recorded with a connected pillbox, the low-self-efficacy estimate was imprecise, and the findings do not establish that the same intervention will work in other populations or platforms.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

The American journal of managed care (PubMed). Remote Monitoring and Self-Efficacy: Implications for Breast Cancer Survivorship Outcomes.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

Smartphone education reduced reported support needs among colorectal cancer caregivers

Azacitidine-venetoclax prolonged event-free survival in a selected induction-eligible AML population

Tailored remote support may help breast cancer survivors with low self-efficacy